Works matching IS 10600280 AND DT 2019 AND VI 53 AND IP 9
Results: 15
Unrecognized Drug Interaction: Ranolazine Adverse Effects Intensified by Darunavir-Cobicistat.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Responding to Manuscript Reviewer and Editor Comments.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System.
- Published in:
- 2019
- By:
- Publication type:
- Letter
A Pseudo-False Negative Urine Methadone Screen in a Patient Treated With Rifampin.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of Pharmacist Impact Within an Interdisciplinary Inpatient Heart Failure Consult Service.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Intravenous Insulin Infusion Protocol Compared With Subcutaneous Insulin for the Management of Hyperglycemia in Critically Ill Adults.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Payers' Perspectives on Pharmacist-Directed Care in a Community Pharmacy Setting.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of Lactation Compatibility Reference Recommendations.
- Published in:
- 2019
- By:
- Publication type:
- journal article
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article